Shopping Cart
- Remove All
- Your shopping cart is currently empty
CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $58 | In Stock | |
5 mg | $148 | In Stock | |
10 mg | $223 | In Stock | |
25 mg | $377 | In Stock | |
50 mg | $537 | In Stock | |
100 mg | $732 | In Stock | |
500 mg | Inquiry | In Stock | |
1 mL x 10 mM (in DMSO) | $163 | In Stock |
Description | CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production. |
In vitro | CL097 (0, 0.5, 2.5, 5, and 10 μg/mL) induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils[1]. CL097 (0.1 μM) induces activation of NF-κB in TLR7-transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells[3]. |
In vivo | in NOD mice, CL097 (5 mg/kg, s.c.) causes a modest specific lysis of the target peptide (∼25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone[2]. |
Alias | CL097 |
Molecular Weight | 242.28 |
Formula | C13H14N4O |
Cas No. | 1026249-18-2 |
Smiles | CCOCc1nc2c([nH]1)c(N)nc1ccccc21 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 95 mg/mL (392.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.